Diagnostics & research
Diagnostics and research tools companies sell the instruments, tests, reagents, and data layers used to detect disease and conduct life-science research.
This segment groups health-care businesses by the economic engine behind the exposure: discovery tools, drug development, scaled pharma manufacturing, or patient-service delivery. The risk profile changes sharply across those layers.
For 13F readers, the tag helps separate long-duration clinical optionality from cash-flowing service or product businesses. It also makes it easier to see when a fund is taking scientific risk versus reimbursement, utilization, or platform-consolidation risk.
- Clinical diagnostics and lab testing
- Genetic testing and sequencing
- Research tools and reagents
- Lab automation and data platforms
- Research funding cycles
- Test reimbursement
- Sequencing adoption
- Hospital and lab capital budgets
Duquesne Family Office LLC
Stanley Druckenmiller · Q4 2025 filed 2026-02-17
Diagnostics, genetic testing, and research-tools businesses.
| Ticker | Name | Value | Instrument |
|---|---|---|---|
| NTRA | NATERA INC | $575M | SH |
| Ticker | Action | Value |
|---|---|---|
| NTRA | Trimmed | -$113M |
| NTRA | Closed | -$16M |